Autolus Therapeutics Plc (AUTL)
NASDAQ:AUTL
Top Page
Autolus Therapeutics
(NASDAQ:AUTL)
Select Model
Select Model
Rating:51Neutral
Price Target:
$1.50
▲(16.28% Upside)
Action:UpgradedDate:01/27/26
The score is held back primarily by weak financial performance (large operating losses and substantial cash burn) and soft technicals (below major moving averages with negative MACD). Offsetting these, the latest earnings update reflects meaningful early commercialization progress and operational milestones, supporting a mid-range score despite valuation being difficult to assess due to negative earnings.
Positive Factors
Commercial launch traction and manufacturing reliability
Sustained commercial adoption across 60 centers with >90% manufacturing success and patient coverage indicates durable operational capability and clinician acceptance. This foundation supports repeatable revenue, network effects in referral patterns, and scale benefits as volumes expand into new indications.
Negative Factors
Heavy negative operating cash flow
Sustained negative operating and free cash flow at this scale signifies ongoing cash burn that will require financing unless offset by faster revenue growth or cost reductions. Persistent cash outflows constrain strategic flexibility, increase dilution risk, and pressure timing for achieving self-funding operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Commercial launch traction and manufacturing reliability
Sustained commercial adoption across 60 centers with >90% manufacturing success and patient coverage indicates durable operational capability and clinician acceptance. This foundation supports repeatable revenue, network effects in referral patterns, and scale benefits as volumes expand into new indications.
Read all positive factors
Autolus Therapeutics (AUTL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$343.32M
Dividend YieldN/A
Average Volume (3M)1.53M
Price to Earnings (P/E)―
Beta (1Y)1.31
Revenue Growth407.86%
EPS Growth30.35%
CountryUS
Employees647
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)N/A
Shares Outstanding266,143,280
10 Day Avg. Volume1,341,335
30 Day Avg. Volume1,527,644
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)1.40
Price to Sales (P/S)59.25
P/FCF Ratio-2.49
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue6.32
Enterprise Value/Gross Profit-2.04
Enterprise Value/Ebitda-1.29
Forecast
1Y Price Target
$8.00Price Target Upside520.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.83
Revenue Forecast (FY)$135.66M
Autolus Therapeutics Business Overview & Revenue Model
Company Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investig...
How the Company Makes Money
Autolus Therapeutics generates revenue primarily through strategic partnerships and collaborations with larger pharmaceutical companies, which provide funding for research and development activities in exchange for rights to commercialize products...
Autolus Therapeutics Earnings Call Summary
Earnings Call Date:Nov 12, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Apr 30, 2026
Earnings Call Sentiment Neutral
While the company has seen a successful launch of Obe-cel in the U.S. with significant market penetration and expansion into new clinical areas, financial challenges such as high cost of sales and increased operational losses present notable challenges. However, the company is well-capitalized to continue its growth and expansion strategies.Positive Updates
Successful Launch of Obe-cel in the U.S.
Achieved $21.1 million in net sales in the third quarter, with a total of $51 million in sales in the first nine months. Established 60 authorized centers across the U.S. with a manufacturing success rate well above 90%.
Negative Updates
High Cost of Sales
Cost of sales totaled $28.6 million, exceeding the product revenue of $21.1 million, indicating room for improvement in efficiency and cost management.
Read all updates
Q3-2025 Updates
Positive
Negative
Successful Launch of Obe-cel in the U.S.
Achieved $21.1 million in net sales in the third quarter, with a total of $51 million in sales in the first nine months. Established 60 authorized centers across the U.S. with a manufacturing success rate well above 90%.
Read all positive updates
Company Guidance
During the third quarter of 2025, Autolus Therapeutics plc reported $21.1 million in net sales for their product Obe-cel, with a deferred revenue of $7.6 million. The company achieved sales of $51 million over the first nine months of the year and authorized 60 treatment centers, meeting their target. Their manufacturing success rate exceeded 90%, and patient access covered more than 90% of U.S. lives. The company is focusing on optimizing operations to improve margins and expand their market beyond adult ALL. Plans include a pivotal study in pediatric ALL, a phase two study in lupus nephritis, and a phase one study in progressive multiple sclerosis. The net loss for the quarter was $79.1 million, a reduction from $82.1 million in the previous year, with cash and marketable securities totaling $36.067 billion as of September 30, 2025.Autolus Therapeutics Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
58
Neutral
Cash Flow
30
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 51.13M | 10.12M | 1.70M | 6.19M | 1.51M | 1.72M |
| Gross Profit | -158.22M | -130.90M | 1.70M | 6.19M | 1.51M | -133.17M |
| EBITDA | -250.91M | -233.07M | -156.77M | -132.24M | -132.47M | -162.58M |
| Net Income | -224.80M | -220.66M | -208.38M | -148.84M | -142.10M | -142.09M |
Balance Sheet | ||||||
| Total Assets | 661.95M | 782.73M | 375.38M | 490.27M | 405.56M | 294.24M |
| Cash, Cash Equivalents and Short-Term Investments | 367.41M | 588.02M | 239.57M | 382.44M | 310.34M | 154.09M |
| Total Debt | 65.83M | 52.63M | 52.97M | 24.26M | 68.01M | 54.16M |
| Total Liabilities | 396.50M | 355.40M | 263.91M | 191.60M | 92.24M | 84.20M |
| Stockholders Equity | 265.45M | 427.32M | 111.47M | 298.67M | 313.32M | 210.03M |
Cash Flow | ||||||
| Free Cash Flow | -278.04M | -241.09M | -156.57M | -123.15M | -126.72M | -132.44M |
| Operating Cash Flow | -254.18M | -206.27M | -145.59M | -112.31M | -117.86M | -117.76M |
| Investing Cash Flow | -311.67M | -394.55M | -10.99M | -10.84M | -8.86M | -14.68M |
| Financing Cash Flow | 27.46M | 589.55M | -883.00K | 223.61M | 284.06M | 74.42M |
Autolus Therapeutics Technical Analysis
Negative
1.29
Price Trends
1.49
Negative
1.52
Negative
1.71
Negative
Market Momentum
-0.06
Positive
34.97
Neutral
5.75
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AUTL, the sentiment is Negative. The current price of 1.29 is below the 20-day moving average (MA) of 1.50, below the 50-day MA of 1.49, and below the 200-day MA of 1.71, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 34.97 is Neutral, neither overbought nor oversold. The STOCH value of 5.75 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AUTL.
Autolus Therapeutics Risk Analysis
Autolus Therapeutics disclosed 86 risk factors in its most recent earnings report. Autolus Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
We expect to continue to expand our development, commercial and regulatory capabilities and have recently developed sales, marketing and distribution capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations. Q3, 2024
2.
The incidence and prevalence for target patient populations for AUCATZYL and our other product candidates have not been established with precision. If the market opportunities for AUCATZYL and our other product candidates are smaller than we estimate, our revenue and ability to achieve profitability will be adversely affected, possibly materially. Q3, 2024
3.
We, and the third parties on whom we rely in part for sales, marketing and distribution capabilities, may not be able to effectively market, sell and distribute AUCATZYL or our other product candidates, if approved. Q3, 2024
Autolus Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $503.83M | -1.68 | -137.70% | ― | ― | -67.41% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $343.32M | -1.37 | -63.76% | ― | 407.86% | 30.35% | |
50 Neutral | $529.03M | -5.28 | -30.40% | ― | ― | -100.71% | |
49 Neutral | $371.37M | -13.08 | -38.92% | ― | ― | 80.95% | |
49 Neutral | $356.73M | -9.89 | -83.21% | ― | ― | -29.73% | |
46 Neutral | $31.24M | -16.53 | -135.79% | ― | -53.67% | 86.75% |
* Healthcare Sector Average
AUTL
Autolus Therapeutics
1.29
-0.36
-21.82%
TVRD
Tvardi Therapeutics
3.33
-12.81
-79.37%
LRMR
Larimar Therapeutics
4.85
2.45
102.08%
BNTC
Benitec Biopharma
10.81
-2.91
-21.24%
DMAC
Diamedica Therapeutics
6.85
2.71
65.46%
CTNM
Contineum Therapeutics, Inc. Class A
13.65
6.20
83.22%
Autolus Therapeutics Corporate Events
Business Operations and Strategy
Autolus Therapeutics Signs Long-Term Lentiviral Supply Agreement
Positive
Jan 26, 2026
On January 21, 2026, Autolus Limited, a subsidiary of Autolus Therapeutics, entered into a new ten-year Master Service Agreement with AGC Biologics S.p.A. for the manufacture and supply of lentiviral vectors, replacing a prior arrangement between ...
Business Operations and StrategyFinancial Disclosures
Autolus issues 2025 AUCATZYL results and 2026 outlook
Positive
Jan 12, 2026
On January 12, 2026, Autolus reported preliminary unaudited net product revenue from AUCATZYL of about $24 million for the fourth quarter of 2025 and approximately $75 million for full-year 2025, the first year of commercial sales, supported by a ...
Business Operations and StrategyExecutive/Board Changes
Autolus Therapeutics Appoints Ryan Richardson to Board
Positive
Dec 2, 2025
On December 1, 2025, Autolus Therapeutics announced the appointment of Ryan Richardson as a Class I director on its Board of Directors. Mr. Richardson, who has over 20 years of experience in healthcare and investment banking, previously served as ...
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
Autolus Therapeutics Appoints New Principal Accounting Officer
Neutral
Nov 12, 2025
On November 7, 2025, Autolus Therapeutics announced the resignation of Rob Dolski as Principal Accounting Officer, with Patrick McIlvenny appointed to the role effective the same day. The company reported third-quarter 2025 financial results, incl...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.